Investor Relations
Our Vision

We look for answers in unexpected places & vigorously test our hypotheses to deliver ground-breaking advances to patients.

Careful Planning for Success

Inmedix specializes in understanding how stress drives an autoimmune disease to excess.

For our first patented project, fibromyalgia (FM), we conducted three clinical studies, including a randomized, placebo-controlled trial negotiated with the FDA, prior to monetizing the value of our research with an international patent portfolio sale. 

For our second project, we found actionable biomarkers based on human electrical signals (ECG) using our innovative and patent-protected 'e-laboratory' in the Azure cloud.  Inmedix is defining Immuno-autonomics and seeks to improve autoimmune disease care through a broader understanding of the autonomic nervous system (ANS). 

We conducted 15 years of research, including a 52-week, double-blind, proof-of-concept study before creating our lead product, the ANS Neuroscan™ diagnostic. We believe our approach to IP and clinical evidence in a setting of great unmet need significantly de-risks Inmedix as an investment opportunity. 

 Inmedix is a privately held corporation (DE) that seeks like-minded individuals and institutions to support our mission of significantly enhancing established therapies for autoimmune disease through assessment, optimization and maintenance of the autonomic nervous system (ANS).  We aim to help patients get their lives back and encourage interested parties to contact our Corporate Development team for more information about supporting Inmedix.